[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100635759":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":20,"centralContacts":26,"locations":36,"responsibleParty":50,"collaborators":19,"id":53,"slug":54,"hasResults":55,"nctId":56,"briefTitle":57,"officialTitle":58,"acronym":19,"eligibilityCriteria":59,"healthyVolunteers":55,"sex":60,"minAge":61,"maxAge":19,"enrollmentInfo":62,"targetDuration":19,"studyType":65,"phases":66,"briefSummary":68,"conditions":69,"keywords":72,"overallStatus":77,"whyStopped":19,"lastUpdateSubmitDate":78,"lastUpdatePostDateStruct":79,"startDateStruct":82,"completionDateStruct":84,"leadSponsor":86,"locationsCount":87},{"fullName":5,"class":6},"Mayo Clinic","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Senyo Health app","EXPERIMENTAL","Patients will utilize the Senyo Health app daily, for 12 weeks",[13],"Other: Senyo Health App",[15],{"type":6,"name":16,"description":17,"armGroupLabels":18,"otherNames":19},"Senyo Health App","The Senyo Health app includes asynchronous cognitive behavioral therapy (CBT) modules, contingency management, behavioral activation, and an interface to interact with the care manager for support in treating the comorbidities of bipolar disorder and substance use disorder.\n\nPatients will engage with the app daily and have weekly check-in visits with the care manager. After the initial 12 week intervention phase, subjects will be followed for 1 year.",[9],null,[21,24],{"name":22,"affiliation":5,"role":23},"Mark A. Frye, MD","PRINCIPAL_INVESTIGATOR",{"name":25,"affiliation":5,"role":23},"Tyler S. Oesterle, MD, MPH",[27,32],{"name":28,"role":29,"phone":30,"phoneExt":19,"email":31},"Kelsey Tuen","CONTACT","507-284-2088","tuen.kelsey@mayo.edu",{"name":33,"role":29,"phone":34,"phoneExt":19,"email":35},"Bryce Leatherman","5074222079","leatherman.bryce@mayo.edu",[37],{"facility":38,"status":19,"city":39,"state":40,"zip":41,"country":42,"countryCode":43,"cosmosGeoPoint":44,"geoPoint":49,"contacts":19},"Mayo Clinic in Rochester","Rochester","Minnesota","55905","United States","US",{"type":45,"coordinates":46},"Point",[47,48],-92.4699,44.02163,{"lat":48,"lon":47},{"type":23,"investigatorFullName":51,"investigatorTitle":52,"investigatorAffiliation":5,"oldNameTitle":19,"oldOrganization":19},"Mark Frye","Principal Investigator","100635759","a-study-of-senyo-health-with-comorbid-alcohol-use-disorder-treatment-in-bipolar-patients-100635759",false,"NCT07556861","A Study Of Senyo Health With Comorbid Alcohol Use Disorder Treatment In Bipolar Patients","Senyo Health App - Comorbid Substance Use Disorder Treatment In Bipolar Patients Using A Telehealth Collaborative Care Platform","Inclusion Criteria:\n\n* History of bipolar I disorder, bipolar II disorder, or schizoaffective disorder of the bipolar type\n* Alcohol use disorder.\n* Ability to read, write, and understand English;\n* Minimum DAST (1+) or AUDIT-C score (3+)\n* Access and willingness to use a mobile device for asynchronous (text) and synchronous (video) engagement with care;\n* Eligibility determined by ASAM Assessment\n\nExclusion Criteria:\n\n* Diagnosed personality pathology as the primary presenting concern based on clinical judgment, severe cognitive impairment (e.g., intellectual disability or dementia), or psychosis;\n* Inability to actively participate in and learn from psychotherapeutic interaction based on clinical evaluation and clinical judgment;\n* Needing a higher level of mental health care as demonstrated by ASAM\\[36\\] assessment;\n* Decline to answer suicidality questions;\n* Already admitted into or about to initiate treatment in another addiction treatment program.\n* Currently attending High School.\n* Pregnancy confirmed by self-report","ALL","18 Years",{"count":63,"type":64},40,"ESTIMATED","INTERVENTIONAL",[67],"NA","The purpose of this study is to examine the effectiveness of a digital integrated behavioral health (IBH) platform in improving substance use outcomes, including treatment retention and substance use frequency and severity in patients with Bipolar Disorder.",[70,71],"Bipolar Disorder","Substance Use (Drugs, Alcohol)",[73,74,75,76],"Bipolar","Substance Use","SUD","Alcohol","NOT_YET_RECRUITING","2026-04-22",{"date":80,"type":81},"2026-04-29","ACTUAL",{"date":83,"type":64},"2026-05-16",{"date":85,"type":64},"2029-01-20",{"name":5,"class":6},1]